PTAB invalidates the last US Zytiga patent

The US Patent and Trademark Office’s (USPTO’s) Patent Trial and Appeal Board (PTAB) has cleared the path for generics of Janssen’s Zytiga (abiraterone acetate) blockbuster to reach the market as early as September this year, after invalidating a key patent shielding the prostate-cancer treatment.